EUDA Health launched the Regenixé iPSC-derived Skin Stem Cell Secretome Mask in its Helixé line, securing exclusive global distribution rights and targeting Malaysia and China through its established Asia-Pacific networks. It regained Nasdaq compliance by keeping its market value of listed securities above $35 million for ten business days ending May 27.
EUDA Health expanded its Helixé skincare line with the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, leveraging cell secretome and cellulose mask technologies to support skin hydration, brightening and recovery. The company secured exclusive global distribution rights from biotech Chemokine Pte Ltd and plans to deploy its Singapore, Malaysia and China networks to capture growth in the Asia-Pacific face mask market.
EUDA regained compliance with Nasdaq Capital Market listing requirements after its market value of listed securities exceeded the $35 million minimum for ten business days ending May 27, resolving the deficiency cited in April and safeguarding its continued listing status.
